SequelSEC

BioCorRx Inc. BICX

Services-Specialty Outpatient Facilities, NEC · CIK 0001443863 · Fiscal year ends 1231

Revenue
$797.24K
Fiscal year ended 2025-12-31
Operating income
-$4.83M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

BioCorRx Inc. (BICX) reported revenue of $797.24K and net income of -$3.44M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from BioCorRx Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Specialty Outpatient Facilities, NEC.

Income

BioCorRx Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$797.24K$7.66K$89.16K$213.84K$48.27K$122.62K$240.26K$376.66K$657.27K$701.77K
Cost of revenueUnavailable$1.67K$35.99K$15.28K$5.88K$95.95K$81.67K$170.95K$323.61K$175.43K
Gross profitUnavailableUnavailable$53.17K$198.56KUnavailable$26.67K$158.59K$205.70K$333.66K$526.34K
Operating income-$4.83M-$5.12M-$3.79M-$4.70M-$5.51M-$7.49M-$5.56M-$4.63M-$2.89M-$2.18M
Net income-$3.44M-$5.11M-$3.77M-$4.38M-$5.21M-$3.51M-$6.05M-$6.58M-$29.71M-$5.90M
Research & development$1.77M$1.48M$891.06K$1.46M$1.61M$4.27M$1.13M$151.77K$450.72KUnavailable
Weighted-average diluted sharesshares 18.49Mshares 10.46Mshares 2.70Mshares 1.45Mshares 1.06Mshares 1.14Mshares 1.14Mshares 2.43Mshares 1.82Mshares 250.19M
Pretax income-$3.51M-$5.21M-$3.77M-$4.38M-$5.21MUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0$0$0UnavailableUnavailableUnavailable
Diluted EPS$-0.19$-0.49UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrative$3.79M$3.61M$2.88M$3.41M$3.74MUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrativeUnavailableUnavailableUnavailableUnavailable$3.74M$3.17M$4.57M$4.42M$2.74M$2.55M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

BioCorRx Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalentsUnavailableUnavailableUnavailableUnavailable$85.84K$592.05K$2.65M$279.77K$11.34K$92.46K
Total assets$2.15M$385.94K$388.89K$766.59K$819.98K$1.83M$3.93M$628.22K$338.90K$470.38K
Current assets$814.47K$118.00K$187.12K$316.91K$228.33K$974.92K$3.05M$319.23K$54.50K$100.86K
Total liabilities$13.67M$12.74M$10.34M$8.97M$7.78M$6.04M$4.99M$6.33M$4.23M$8.60M
Current liabilities$8.31M$8.21M$6.43M$5.36M$4.39M$3.05M$2.55M$6.13M$1.64M$2.45M
Total equity incl. NCI-$11.53M-$12.36M-$9.95M-$8.20M-$6.96M-$4.21M-$1.06M-$5.71M-$3.89M-$8.13M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$143.42K$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$253.46K$0$740$35.38K$1.50K$500$750$8.00K$29.95KUnavailable
Goodwill$563.16K$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable$0$99.86KUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$4.03M$3.02M$2.47M$2.01M$1.78M$1.18M$709.35K$655.65K$714.82K$768.34K

Cash flow

BioCorRx Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow-$2.30M-$1.10M-$1.85M-$2.04M-$3.54M-$2.15M-$2.94M-$1.83M-$2.54M-$2.00M
Capital expendituresUnavailableUnavailableUnavailable$0$2.02K$0Unavailable$10.00KUnavailable$305.65K
Investing cash flowUnavailableUnavailableUnavailable$0-$50.00K-$9.23K-$121.79K-$55.95K-$2.97K-$328.24K
Financing cash flow$2.35M$1.12M$1.85M$2.02M$3.08M$107.30K$5.42M$2.15M$2.41M$2.25M
Net change in cashUnavailableUnavailableUnavailableUnavailable-$506.22K-$2.05M$2.37M$268.43K-$131.11K-$77.60K
Stock-based compensation$592.60K$1.22M$277.06K$354.51K$209.52K$355.04K$1.97M$2.81M$830.79K$582.35K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$44.00K$33.14K$26.81K$27.45K$64.33K$77.25K$29.41K$7.35K$33.89K$30.25K

Derived

BioCorRx Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailable-$3.54M-$2.15MUnavailableUnavailableUnavailable-$2.31M
Gross marginUnavailableUnavailable59.6%92.9%Unavailable21.8%66.0%54.6%50.8%75.0%
Operating margin-606.0%-66829.8%-4248.3%-2197.0%-11414.7%-6109.9%-2314.7%-1228.2%-439.8%-310.9%
FCF marginUnavailableUnavailableUnavailableUnavailable-7332.8%-1754.9%UnavailableUnavailableUnavailable-328.5%
SBC / revenue74.3%15906.8%Unavailable165.8%434.0%289.5%818.2%745.3%126.4%83.0%
Current ratio0.10x0.01x0.03x0.06x0.05x0.32x1.19x0.05x0.03x0.04x
Revenue YoY growth10301.1%-91.4%-58.3%343.0%-60.6%-49.0%-36.2%-42.7%-6.3%Unavailable
Net margin-431.5%-66616.1%-4228.9%-2046.8%-10794.3%-2859.6%-2517.4%-1748.1%-4519.5%-841.3%
R&D / revenue221.9%19346.1%999.4%682.5%3326.8%3485.4%468.3%40.3%68.6%Unavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailable4.2%0.0%UnavailableUnavailableUnavailable43.6%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BICX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2024-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2021-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.